title: Circulating endothelial cells as biomarkers for patients receiving bevacizumab.
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertolini
authors.forename: Patrizia
authors.initials: P
authors.lastname: Mancuso
authors.forename: Yuval
authors.initials: Y
authors.lastname: Shaked
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015415:Biomarkers / Q000097:blood; D042783:Endothelial Cells / Q000473:pathology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab